A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Cancer Immunology, Immunotherapy

Volumn 61, Issue 3, 2012, Pages 373-384

  Rahma, Osama E ^a   Ashtar, Ed ^a,b   Czystowska, Malgorzata ^c   Szajnik, Marta E ^c,d   Wieckowski, Eva ^c   Bernstein, Sarah ^a   Herrin, Vincent E ^e   Shams, Mortada A ^a   Steinberg, Seth M ^a   Merino, Maria ^f   Gooding, William ^c   Visus, Carmen ^c   DeLeo, Albert B ^c   Wolf, Judith K ^g   Bell, JeVrey G ^h   Berzofsky, Jay A ^a   Whiteside, Theresa L ^c   Khleif, Samir N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of Pittsburgh Cancer Institute ^*  (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e UNIVERSITY OF MISSISSIPPI   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h RIVERSIDE METHODIST HOSPITAL   (United States)

Author keywords

Cancer vaccine; IL 2; Ovarian cancer; p53

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MONTANIDE ISA 51; P53 [264-272]; PEPTIDE VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; HLA A2 ANTIGEN; PROTEIN P53; SUBUNIT VACCINE;

ADULT; AGED; AMNESIA; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; CELL EXPANSION; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DENDRITIC CELL; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FEVER; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PELVIS PAIN SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RIGOR; SIDE EFFECT; SURVIVAL TIME; T LYMPHOCYTE; VOMITING; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE; VACCINATION;

ADULT; AGED; CANCER VACCINES; COHORT STUDIES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FATIGUE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; LYMPHOPENIA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RISK FACTORS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VACCINATION; VACCINES, SUBUNIT;

EID: 84860790830     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1100-9     Document Type: Article

References (47)

1. Khleif SN, Abrams SI, Hamilton JM et al (1999) A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22:155-165 (Pubitemid 29135900)
2. Toubaji A, Achtar M, Provenzano M et al (2008) Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 57:1413-1420
3. Phan GQ, Touloukian CE, Yang JC et al (2003) Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26:349-356 (Pubitemid 36858719)
4. Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117:1195-1203
5. Bubenik J (2001) Genetically engineered dendritic cell-based cancer vaccines (review). Int J Oncol 18:475-478
6. Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in Wrst-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563-570
7. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016-4026 (Pubitemid 46606217)
8. Lu W, Arraes LC, Ferreira WT, Andrieu JM (2004) Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10:1359-1365 (Pubitemid 40022718)
9. Su Z, Dannull J, Yang BK et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174:3798-3807 (Pubitemid 40354093)
10. Heiser A, Coleman D, Dannull J et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109:409-417 (Pubitemid 34141815)
11. Su Z, Dannull J, Heiser A et al (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127-2133 (Pubitemid 36538616)
12. Dannull J, Su Z, Rizzieri D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623-3633 (Pubitemid 43121851)
13. Gabrilovich DI, Ciernik IF, Carbone DP (1996) Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101-110
14. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP (1996) Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 170:111-119
15. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483-490 (Pubitemid 27158075)
16. Kichler-Lakomy C, Budinsky AC, Wolfram R et al (2006) Deficiencies in phenotype expression and function of dendritic cells from patients with early breast cancer. Eur J Med Res 11:7-12 (Pubitemid 43216405)
17. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147 (Pubitemid 36287518)
18. Lesterhuis WJ, de Vries IJ, Schuurhuis DH et al (2006) Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol 17:974-980 (Pubitemid 43778989)
19. Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky JA (1993) Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol 5:849-857 (Pubitemid 23241756)
20. Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB (2007) Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin Immunol 125:43-51 (Pubitemid 47374535)
21. Svane IM, Pedersen AE, Johnsen HE et al (2004) Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 53:633-641 (Pubitemid 38858337)
22. Svane IM, Pedersen AE, Johansen JS et al (2007) Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 56:1485-1499 (Pubitemid 47024713)
23. DeLeo AB, Whiteside TL (2008) Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 7:1031-1040
24. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327 (Pubitemid 28144091)
25. Lotem M, Shiloni E, Pappo I et al (2004) Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 90:773-780 (Pubitemid 38406585)
26. Qian J, Dong Y, Pang YY et al (2006) Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 118:3022-3029
27. Toubaji A, Hill S, Terabe M et al (2007) The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 25:5882-5891 (Pubitemid 47043218)
28. Weber J, Sondak VK, Scotland R et al (2003) Granulocyte-macrophage- colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97:186-200 (Pubitemid 36033878)
29. Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543 (Pubitemid 23111402)
30. Whiteside T (2005) ELISPOT assays. Assessment of cellular immune responses to anti-cancer vaccines. In: Nagorsen D, Marincola FM (eds.) Analyzing T cell responses. Springer, Dordrecht, pp 143-156
31. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL (2007) The frequency and suppressor function of CD4+ CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301-6311 (Pubitemid 350075018)
32. Bergmann C, Strauss L, Wang Y et al (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14:3706-3715
33. Markovic SN, Suman VJ, Ingle JN et al (2006) Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 29:352-360 (Pubitemid 44197539)
34. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238 (Pubitemid 32524454)
35. Lechler R, Ng WF, Steinman RM (2001) Dendritic cells in transplantation-friend or foe? Immunity 14:357-368
36. Cools N, Van Tendeloo VF, Smits EL et al (2008) Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/ IL-10 double-positive CD4+ regulatory T cells. J Cell Mol Med 12:690-700 (Pubitemid 351555146)
37. Roncarolo MG, Levings MK, Traversari C (2001) Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 193:F5-F9 (Pubitemid 32524446)
38. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243-251 (Pubitemid 32574281)
39. Maier T, Tun-Kyi A, Tassis A et al (2003) Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102:2338-2344 (Pubitemid 37193567)
40. Bedrosian I, Mick R, Xu S et al (2003) Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21:3826-3835 (Pubitemid 46606238)
41. de Vries IJ, Lesterhuis WJ, Barentsz JO et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23:1407-1413 (Pubitemid 41679393)
42. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al (2004) Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22:4474-4485 (Pubitemid 41185113)
43. Escobar A, Lopez M, Serrano A et al (2005) Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 142:555-668
44. Wojtowicz ME, Hamilton MJ, Benrnstein S et al (2000) Clinical trial of mutant ras peptide vaccination along with IL-2 or GM-CSF. Proc Am Soc Clin Oncol 19:463a (abstr 1818)
45. Lemoine FM, Cherai M, Giverne C et al (2009) Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 35:569-581
46. Green DS, Dalgleish AG, Belonwu N, Fischer MD, Bodman-Smith MD (2008) Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 159:606-614
47. Simon RM, Steinberg SM, Hamilton M et al (2001) Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 19:1848-1854 (Pubitemid 32230888)